The European Association of Urology (EAU) renal cell carcinoma (RCC) guidelines have updated recommendations regarding diagnosis, treatment of localised and advanced disease, and surveillance strategies after treatment.

The update includes the recommendation not to use adjuvant therapy with sunitinib, pazopanib or axitinib, recommendations on the treatment of non-RCC kidney tumours, and recommendations on the use of cytoreductive nephrectomy for advanced/metastatic RCC.

Read the full guidelines on the EAU website here